Helical volumetric modulated arc therapy for treatment of craniospinal axis.

PURPOSE: Volumetric modulated arc therapy (VMAT) can be used with multiple isocenters to provide an effective treatment of the craniospinal axis. Additional efficiency can be achieved by simultaneously applying linear couch motion to generate a helical arc trajectory. This study investigated the treatment planning and delivery of helical VMAT for treatment of the craniospinal axis. METHODS AND MATERIALS: VMAT plans were retrospectively created for 5 patients. The first plan consisted of multiple separate arcs. A second plan consisted of a single helical arc with a pitch of 10 cm. Three additional plans consisted of multiple helical arcs with the beam rotating alternately clockwise and counterclockwise to avoid the need for the gantry to pass through 180°. The three plans had a pitch of 5, 10, and 15 cm. For 1 of the patients, three possible plans with alternate gantry motion and a pitch of 10 cm were delivered helically, and the dose was verified. RESULTS: Relative to the plan with separate arcs, the continuous helical plan produced a mean objective value of 104.0% ± 14.8% (standard deviation), and the alternating helical plans produced an objective value of 118.9% ± 9.8%, 102.3% ± 13.5%, and 101.5% ± 15.8% for a pitch of 5 cm, 10 cm, and 15 cm, respectively (with lower values representing better plans). For the delivered plans, taking a mean of 17 min 51 s to deliver, a mean of 97.1% of the measurements were within 4% and 4 mm of the planned dose. CONCLUSIONS: A continuous helical VMAT plan provides comparable dose quality to a plan with separate VMAT arcs. Comparable quality is also produced by an alternating helical plan, provided the pitch is chosen appropriately. Alternating helical plans have been delivered and verified successfully. Alternating helical delivery offers the ultimate delivery efficiency for intensity-modulated radiotherapy for the craniospinal axis.

Development and evaluation of multiple isocentric volumetric modulated arc therapy technique for craniospinal axis radiotherapy planning.

PURPOSE: To develop and compare a volumetric modulated arc therapy (VMAT) technique with conventional radiotherapy for craniospinal irradiation with respect to improved dose conformity and homogeneity in the planning target volume (PTV) and to reduced dose to organs at risk (OAR). METHODS AND MATERIALS: Conventional craniospinal axis radiotherapy plans of 5 patients were acquired. The median (range) length of the PTV was 58.9 (48.1-83.7) cm. The 6-MV VMAT plans were inversely planned with one isocenter near the base of the brain and the minimum number of isocenters required for the specified lengths of spine. The plans were optimized with high weighting for PTV coverage and low weighting for OAR sparing. Conformity and heterogeneity indices, dose-volume histograms, mean doses, and non-PTV integral doses from the two plans (prescription dose 23.4 Gy in 13 fractions) were compared. RESULTS: The median (range) conformity index of VMAT was 1.22 (1.09-1.45), compared with 1.69 (1.44-2.67) for conventional plans (p = 0.04). The median (range) heterogeneity index was also lower for VMAT compared with conventional plans: 1.04 (1.03-1.07) vs. 1.12 (1.09-1.19), respectively (p = 0.04). A significant reduction of mean and maximum doses was observed in the heart, thyroid, esophagus, optic nerves, and eyes with VMAT when compared with conventional plans. A decrease in body V(10Gy) was observed, but for 4 of 5 patients non-PTV integral dose was increased with VMAT when compared with the conventional plans. CONCLUSIONS: A VMAT technique to treat the craniospinal axis significantly reduces OAR dose, potentially leading to lower late organ toxicity. However, this is achieved at the expense of increased low-dose volumes, which is inherent to the technique, carrying a potentially increased risk of secondary malignancies.

Evaluation of the Delta4 phantom for IMRT and VMAT verification.

The Delta(4) diode array phantom (Scandidos, Uppsala, Sweden) was evaluated for verification of segmental intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) on an Elekta linear accelerator (Crawley UK). The device was tested for angular sensitivity by irradiating it from 36 different gantry angles, and the responses of the device to various step-and-shoot segment doses and dose rates were evaluated using an ionization chamber as a comparison. The phantom was then compared with ionization chamber and film results for two prostate and pelvic nodes IMRT plans, two head and neck IMRT plans and two lung VMAT plans. These plans were calculated using Pinnacle(3) (Philips Radiation Oncology Systems, Madison, WI). The uniformity of angular response was better than 0.5% over the range of gantry angles. The uniformity of response of the Delta(4) to different segment monitor units and dose rates was better than 0.5%. The assessment of the IMRT and VMAT plans showed that the Delta(4) measured a dose within 2.5% of the ionization chamber, and compared to film recorded a slightly larger region (range -2% to +7%) agreeing with the planned dose to within 3% and 3 mm. The Delta(4) is a complex device and requires careful benchmarking, but following the successful completion of these measurements, the Delta(4) has been introduced into clinical use.

Commissioning of volumetric modulated arc therapy (VMAT).

PURPOSE: Volumetric modulated arc therapy (VMAT) involves the simultaneous use of dynamic multileaf collimator (DMLC) techniques and gantry arcing; appropriate quality assurance is therefore required. This article describes the development and implementation of procedures for commissioning VMAT on a commercial linear accelerator (Elekta PreciseBeam VMAT with MLCi and Beam Modulator heads). MATERIALS AND METHODS: Tests for beam flatness and symmetry at the variable dose rates required for VMAT were performed. Multileaf collimator (MLC) calibration was investigated using dynamic prescriptions. The cumulative dose delivered by a sliding window aperture was measured and compared with calculated values. Rotational accuracy was evaluated using dynamic prescriptions which required accurate correlated motion of both gantry and MLC leaves. Finally, measured and calculated dose distributions for complete VMAT treatment plans were compared and evaluated. RESULTS: Beam symmetry was found to be better than 3% down to dose rates of 75 MU/min. MLC calibration provided continuity of dose at match planes of better than 4%, which was comparable to interleaf leakage effects. Integrated sliding window doses were within 3% of those calculated. Tests for rotational accuracy showed uniformity of peripheral dose mostly within +/-4% of local control point dose, or approximately +/-0.2% of total central dose. A two-arc prostate case showed an absolute dose difference between calculations and measurements of less than 3%, with gamma (3% and 3 mm) of better than 95%. CONCLUSIONS: VMAT has been successfully commissioned and has been introduced into clinical use. The Elekta DMLC has also been shown to be suitable for sliding window delivery.

Treatment of lung cancer using volumetric modulated arc therapy and image guidance: a case study.

BACKGROUND: Volumetric modulated arc therapy (VMAT) is a radiotherapy technique in which the gantry rotates while the beam is on. Gantry speed, multileaf collimator (MLC) leaf position and dose rate vary continuously during the irradiation. For optimum results, this type of treatment should be subject to image guidance. The application of VMAT and image guidance to the treatment of a lung cancer patient is described. MATERIAL AND METHODS: In-house software AutoBeam was developed to facilitate treatment planning for VMAT beams. The algorithm consisted of a fluence optimisation using the iterative least-squares technique, a segmentation and then a direct-aperture optimisation. A dose of 50 Gy in 25 fractions was planned, using a single arc with 35 control points at 10 degrees intervals. The resulting plan was transferred to a commercial treatment planning system for final calculation. The plan was verified using a 0.6 cm(3) ionisation chamber and film in a rectangular phantom. The patient was treated supine on a customised lung board and imaged daily with cone-beam CT for the first three days then weekly thereafter. RESULTS: The VMAT plan provided slightly improved coverage of the planning target volume (PTV) and slightly lower volume of lung irradiated to 20 Gy (V(20)) than a three-field conformal plan (PTV minimum dose 85.0 Gy vs. 81.8 Gy and lung V(20) 31.5% vs. 34.8%). The difference between the measured and planned dose was -1.1% (measured dose lower) and 97.6% of the film passed a gamma test of 3% and 3mm. The VMAT treatment required 90 s for delivery of a single fraction of 2 Gy instead of 180 s total treatment time for the conformal plan. CONCLUSION: VMAT provides a quality dose distribution with a short treatment time as shown in an example of a lung tumour. The technique should allow for more efficient delivery of high dose treatments, such as used for hypofractionated radiotherapy of small volume lung tumours, and the technique may also be used in conjunction with Active Breathing Control, where fewer breath holds will be required.

Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET.

PURPOSE: To evaluate the efficacy and toxicity of hypofractionated stereotactic radiotherapy in the management of locally recurrent or residual central nervous system (CNS) primitive neuroectodermal tumors (PNETs). PATIENTS AND METHODS: Between 1991 and 2005, 12 patients with locally recurrent medulloblastoma and two patients with residual supratentorial PNET were treated with hypofractionated stereotactic conformal radiotherapy (SCRT). Nine patients were treated for first recurrence, two patients after the 2nd, and one patient after 3rd recurrence. Median age at diagnosis was 20 years (range: 4-35 years) and median age at SCRT 25 years (range: 7-41 years). Nine of 12 patients underwent resection at recurrence and 13 patients received at least one cycle of chemotherapy prior to SCRT. All received focal SCRT (30-40 Gy/6-8 #) using non-coplanar arcs (n = 6) or fixed conformal non-coplanar fields (n = 8). RESULTS: Median overall survival was 29 months (95% CI: 6-51 months) and median progression-free survival was 12 months (95% CI: 5-19 months). Local progression-free survival at 1 and 3 years was 80% (95% CI: 55-100%) and 48% (95% CI: 11-85%). Causes of death were recurrent CNS disease (n = 7), herpes encephalitis (n = 1), and metastatic PNET outside the CNS (n = 1). CONCLUSION: Hypofractionated SCRT provides effective local control with acceptable toxicity for patients with recurrent localized PNET. However, overall long-term disease control is rare and limited by the occurrence of CSF mediated relapses, which thus could benefit from intensive systemic chemotherapy as part of the primary relapse strategy even in local recurrences. Larger multi-national studies will be necessary to assess the value of such combined treatment approaches.

A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.

BACKGROUND AND PURPOSE: Intensity modulated radiotherapy (IMRT) allows the delivery of higher and more homogeneous radiation dose to head and neck tumours. This study aims to determine the safety of dose-escalated chemo-IMRT for larynx preservation in locally advanced head and neck cancer. METHODS: Patients with T2-4, N1-3, M0 squamous cell carcinoma of the larynx or hypopharynx were treated with a simultaneous-boost IMRT. Two radiation dose levels (DL) were tested: In DL 1, 63 Gy/28F was delivered to primary tumour and involved nodes and 51.8 Gy/28F to elective nodes. In DL 2, the doses were 67.2 Gy/28F and 56 Gy/28F, respectively, representing a 9% dose escalation for the primary. All patients received 2 cycles of neoadjuvant cisplatin and 5-fluorouracil, and concomitant cisplatin. Acute (NCICTCv.2.0) and late toxicity (RTOG and modified LENTSOM) were collected. RESULTS: Thirty patients were entered, 15 in each dose level. All patients completed the treatment schedule. In DL 1, the incidences of acute G3 toxicities were 27% (pain), 20% (radiation dermatitis), 0% (xerostomia) and 67% required gastrostomy tubes. For DL 2 the corresponding incidences were 40%, 20%, 7%, and 87%. G3 dysphagia and pain persisted longer in DL 2. With regard to mucositis, a prolonged healing time for DL 2 was found, with prevalence of G2 of 58% in week 10. No acute grade 4 toxicity was observed. At 6 months, 1 patient in DL 2 had G3 late toxicity (dysphagia). No dose limiting toxicity was found. Complete response rates were 80% in DL 1, and 87% in DL 2. CONCLUSION: Moderately accelerated chemo-IMRT is safe and feasible with good compliance and acceptable acute toxicity. Dose escalation was possible without a significant difference in acute toxicity. Longer follow-up is required to determine the incidence of late radiation toxicities, and tumour control rates.

A comparison of CT- and ultrasound-based imaging to localize the prostate for external beam radiotherapy.

PURPOSE: This study assesses the accuracy of NOMOS B-mode acquisition and targeting system (BAT) compared with computed tomography (CT) in localizing the prostate. METHODS AND MATERIALS: Twenty-six patients were CT scanned, and the prostate was localized by 3 observers using the BAT system. The BAT couch shift measurements were compared with the CT localization. Six of the patients had gold markers present in the prostate, and the prostate movement determined by BAT was compared with the movement determined by the gold markers. RESULTS: Using the BAT system, the 3 observers determined the prostate position to be a mean of 1-5 mm over all directions with respect to the CT. The proportion of readings with a difference >3 mm between the observers was in the range of 25% to 44%. The prostate movement based on gold markers was an average of 3-5 mm different from that measured by BAT. The literature assessing the accuracy and reproducibility on BAT is summarized and compared with our findings. CONCLUSIONS: We have found that there are systematic differences between the BAT-defined prostate position compared with that estimated on CT using gold grain marker seeds.

Treatment of extensive scalp lesions with segmental intensity-modulated photon therapy.

PURPOSE: To compare static electron therapy, electron arc therapy, and photon intensity-modulated radiation therapy (IMRT) for treatment of extensive scalp lesions and to examine the dosimetric accuracy of the techniques. METHODS AND MATERIALS: A retrospective treatment-planning study was performed to evaluate the relative merits of static electron fields, arcing electron fields, and five-field photon IMRT. Thermoluminescent dosimeters (TLD) were used to verify the accuracy of the techniques. The required thickness of bolus was investigated, and an anthropomorphic phantom was also used to examine the effects of air gaps between the wax bolus used for the IMRT technique and the patient's scalp. RESULTS: Neither static nor arcing electron techniques were able to provide a reliable coverage of the planning target volume (PTV), owing to obliquity of the fields in relation to the scalp. The IMRT technique considerably improved PTV dose uniformity, though it irradiated a larger volume of brain. Either 0.5 cm or 1.0 cm of wax bolus was found to be suitable. Air gaps of up to 1 cm between the bolus and the patient's scalp were correctly handled by the treatment-planning system and had negligible influence on the dose to the scalp. CONCLUSIONS: Photon IMRT provides a feasible alternative to electron techniques for treatment of large scalp lesions, resulting in improved homogeneity of dose to the PTV but with a moderate increase in dose to the brain.

A comparison of forward and inverse planned conformal, multi segment and intensity modulated radiotherapy for the treatment of prostate and pelvic nodes.

BACKGROUND AND PURPOSE: Full inverse planned intensity modulated radiotherapy (IMRT) may be indicated to treat concave targets like prostate and pelvic nodes, because concave dose distributions cannot be generated with conformal radiotherapy (CRT). We investigated whether this concave dose distribution can be produced using simplified forward planned multi segment radiotherapy (MSRT). PATIENTS AND METHODS: CRT, MSRT and IMRT dose distributions were calculated and compared for five patients treated in our current IMRT prostate and pelvic node dose escalation trial. The same beam arrangement was used for CRT, MSRT and IMRT, increasing the number of segments. The MSRT concave dose distribution was realised regarding left and right pelvic nodes as two separate targets. The IMRT dose distribution had been used to treat the patients using a step and shoot delivery. RESULTS: Contrary to CRT, forward planned MSRT concave dose distributions had improved target coverage at lower or equivalent bowel doses than inverse planned IMRT. The five MSRT beams had a maximum of three segments per beam. Both lateral beams had two segments to deliver the two dose levels to prostate and nodes. The posterior field needed a third segment to avoid using a central block. The two anterior oblique beams needed a third segment to account for the different beam weighting because the nodes were irradiated partially using four and partially using five beams. Inverse planned IMRT used up to 15 segments in any one beam, with an average of 11.4 per beam. CONCLUSIONS: Concave dose distributions for prostate and pelvic node treatment were generated using forward planned multi segment techniques. The plans met clinical constraints used in our IMRT protocol. MSRT presented a significant advantage over both CRT and IMRT.

Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement.

BACKGROUND AND PURPOSE: Two systems have been developed for treating patients with locally advanced prostate cancer using intensity-modulated radiotherapy (IMRT): one using dynamic multi-leaf collimator delivery and the other using step-and-shoot. This paper describes the clinical implementation of these two techniques, and presents results from the first 14 patients treated in a clinical setting (nine dynamic, five step-and-shoot). PATIENTS AND METHODS: Dynamic treatments were planned using Corvus, and step-and-shoot using Helax-TMS; all were delivered using Elekta accelerators. Prior to the first clinical treatments, validation measurements were carried out for each system, including measurements for a complete IMRT treatment. The reproducibility of dynamic delivery and the characteristics of the accelerator for low-monitor-unit (MU) deliveries were also assessed. An extensive quality assurance (QA) program was performed for each of the patients. Additionally, timing measurements were carried out to assess the practicalities of the technique. RESULTS: The planning objectives were met in most cases. Absolute doses for complete IMRT treatments were within 2%, on average, with dose distributions generally showing agreement within 3% or 3 mm. Beam modulation measurements made throughout each patient's treatment indicated that both delivery methods were reproducible. The dynamic plans required an average of 765 MU per beam, with a treatment delivery time of 14 min; corresponding results for step-and-shoot plans were 105 MU and 10 min. CONCLUSIONS: Two IMRT techniques for this group of patients have been successfully implemented in the clinic. The more complex dynamic treatments showed no advantages over the step-and-shoot approach. QA results have shown accurate and reproducible delivery for both techniques, giving increased confidence in the techniques and allowing a reduction in the QA program.

Commissioning and implementation of a stereotactic conformal radiotherapy technique using a general-purpose planning system.

The purpose of this paper is to report on commissioning and clinical implementation of a customized system for pediatric stereotactic conformal radiotherapy (SCRT). The system is based on the Pinnacle treatment-planning system and its interfaces with other equipment: (1) Beam models were optimized for our compact blocking system and a new LINAC. (2) Three CT-to-density conversion tables were evaluated, one using tabulated data for a commercial phantom, the second including additional points from the manufacturer's data for the inserts in an in-house phantom, and the third using measured densities for the in-house phantom materials combined with tabulated data for the commercial phantom. (3) Blocks were transferred to a computerized block cutter using in-house software that extracted the block shape from the export file and custom-fitted the additional necessary shapes. (4) In the absence of a DICOM RT Image link, a method based on screen data capture was used to export digitally reconstructed radiographs (DRRs) to two portal imaging systems for treatment verification. Lens shielding by multileaf collimation in the anterior-posterior isocenter verification field was investigated. (1) Computed dose distributions using the beam models agreed with measurements well within published acceptability criteria. A difference of up to 1.0 mm was measured between the beam's eye views of aperture blocks and computed 50% isodose contours for a 2 x 2 x 2 mm dose calculation grid. (2) The third table, which included measured densities, improved the accuracy of the calculated isocenter dose by up to 0.5% in typical patient SCRT treatments and up to 1.0% in a phantom with 5-cm diameter inhomogeneity inserts. (3) The block export and customization process was shown to introduce no additional uncertainty. A 1-mm block production uncertainty was measured using film dosimetry on six blocks. (4) The DRR transfer method did not introduce uncertainty into the process. Verification field shielding reduced lens dose by 12 to 15 times. In conclusion, this customized system for planning and verification of pediatric SCRT provides a high level of precision as well as reasonable practical efficiency.

Verification of inverse planning and treatment delivery for segmental IMRT.

With intensity-modulated radiotherapy (IMRT), it is important that the inverse planning process yields the most appropriate dose distribution for the patient and that the delivered dose then corresponds to the planned dose. This paper presents methods by which the inverse planning and delivery of segmental (step-and-shoot) IMRT can be verified, and gives results for a typical treatment planning system (Pinnacle3 v6.2b, Philips Radiation Oncology Systems, Milpitas, CA). Inverse planning was assessed by observing the reduction in objective function as fields were successively added to three-field prostate, esophagus, and thyroid plans. The ability of the treatment planning system to calculate dose for a segmented field was examined by creating a stepped field with five successively narrowing segments. The complete planning process was then investigated by using two orthogonal IMRT fields to create a homogeneous dose distribution in a cubic water phantom. Finally, a clinical situation was simulated by creating a five-field segmental IMRT plan for a lung target in an anthropomorphic phantom. A conformal plan was also compared for context. Addition of fields to inverse plans generally resulted in a reduction of objective function, indicating consistency of inverse planning solutions. Planned dose for fields with stepped intensity agreed with ionization chamber measurements to within 5%. For orthogonal fields, planned dose distributions agreed well with dose measured using film and agreed with ionization chamber measurements to within 3%. For the anthropomorphic phantom, the standard deviation of difference between planned and measured dose was 4%. Although no consensus has yet been reached on what constitutes an acceptable IMRT plan, these results indicate that step-and-shoot IMRT can be planned and delivered using the system described with comparable accuracy to a standard conformal treatment.

Stereotactically guided conformal radiotherapy for progressive low-grade gliomas of childhood.

PURPOSE: To describe the rationale, technique, and early results of stereotactically guided conformal radiotherapy (SCRT) in the treatment of progressive or inoperable low-grade gliomas (LGGs) of childhood. METHODS AND MATERIALS: Between September 1994 and May 1999, 14 children (median age 6 years, range 5-16) with LGG were treated with SCRT at the Royal Marsden NHS Trust. Tumors were located at the optic chiasm (n = 9), third ventricle (n = 2), hypothalamus, craniocervical junction, and pineal region (each n = 1). Four patients received chemotherapy before SCRT. Immobilization was in a Gill-Thomas-Cosman frame (n = 12) and subsequently in a specially designed pediatric version of the frame (n = 2). Stereotactic coordinates and the tumor were defined by CT scanning with a fiducial system and MRI fusion. The median tumor volume was 19.5 cm(3) (range 7.5-180). The planning target volume was defined as the area of enhancing tumor plus a 5-10-mm margin. The treatment technique consisted of 4 isocentric, noncoplanar, conformal, fixed fields. Treatment was delivered in 30-33 daily fractions to a total dose of 50-55 Gy. RESULTS: SCRT was well tolerated, with transient hair loss the only acute toxicity. The median follow-up was 33 months (range 2-53). At 6 months after SCRT, 4 of 12 children with neurologic deficits improved and 5 remained stable. Twelve children were available for MRI evaluation. Two had a complete response, 6 a partial response, and 4 stable disease. One child with optic chiasm glioma had local progression at 25 months, and 1 developed diffuse leptomeningeal disease without local progression at 27 months. The 3-year local progression-free survival and overall survival rate after SCRT was 87% and 100%, respectively, compared with 89% and 98% for an historic control treated with conventional RT. New endocrine deficiencies were noted in 2 children after a follow-up of 20 and 23 months. CONCLUSION: SCRT is a feasible, high-precision technique of RT for children with LGGs for whom RT is considered appropriate. The local control and acute toxicity of SCRT are comparable to a historic control of patients with conventionally delivered RT. The frequency of delayed hypothalamic-pituitary axis dysfunction reflects tumor location adjacent to the hypothalamus and pituitary. Additional follow-up is required to demonstrate that SCRT contributes to a reduction in treatment-related late toxicity, while maintaining the local control achieved with conventionally delivered RT in children with progressive LGGs.